A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane� (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with e

To determine whether PYM50028 exhibits clinical benefit in the treatment of subjects with early-stage Parkinson�s disease (PD), as assessed by the Unified Parkinson�s Disease Rating Scale score for Parts II and III combined (UPDRS II/III), compared with placebo.